BLUE Stock Recent News
BLUE LATEST HEADLINES
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Medallion shareholders vote on the BLUE proxy card “FOR” ONLY the two incumbent candidates nominated by the Board of Directors, Robert M. Meyer and David L.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On December 8, 2023, bluebird announced that it had receive.
NEW YORK , May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.
NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
BENSALEM, Pa. , May 22, 2024 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK , May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, NY / ACCESSWIRE / May 20, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80686&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / May 20, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80689&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80646&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80639&wire=1 or contact Joseph E. Levi, Esq.